Pernix Therapeutics Holdings Inc (NASDAQ:PTX)
Pernix Therapeutics Holdings, Inc. (PTX), a specialty pharmaceutical company yesterday reported their fourth quarter and full year 2016 financial results. Pernix reported fourth quarter revenues of $30.1 million which was down 27% compared to fourth quarter of the previous year which was $41.5 million.
Pernix Therapeutics Holdings, Inc. CEO’s Comments
“Since July 2016, when we restructured our sales force, we have achieved significant progress in improving the performance of our business,” said John Sedor, Chairman and Chief Executive Officer of Pernix Therapeutics. “Moreover, our prescription fulfillment program, Pernix Prescriptions Direct, continues to drive uptake of Treximet and Silenor. We remain focused on improving our commercial execution and driving further growth of our core brands. In addition, our business returned to positive adjusted EBITDA during the second half of 2016.”
“We were pleased to reach a resolution with GSK,” said Graham Miao, President and Chief Financial Officer. “We continue to assess various alternatives in order to proactively address our liquidity and capital structure in a constructive manner, including strategic and refinancing alternatives, asset sales, and mergers and acquisitions.” Globe Newswire
PTX Technical Analysis
PTX opened trading yesterday at $4.22 which was up from the previous day’s trading close of $4.17. Shares closed trading yesterday at $4.06 and spiked down after market to $3.50, equivalent to a 14% decrease from the closing price. Taking a look at the daily chart we can see that the last time PTX traded below these levels we have to go back to March 7th when it traded at $3.46.
Taking a closer look at the daily chart we can see that before the spike down PTX had been in an overall upward trend dating back to December 30th, 2016 when it traded at $1.94. PTX has a float of 8.07 million shares and traded below the normal daily trading volume on Tuesday.
For day trading purposes, I would like to see HTGM open trading on Wednesday below $3.70 and if it does I would be looking to place my limit order to take a short position at the bell. My stop order would be $0.10 from my entry position fearing anything more than that and the stock would start to fill in the gap down.
Company Profile
Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products. The company’s products comprise Treximet, a medication indicated for the acute treatment of migraine attacks in adults; Zohydro ER with BeadTek, an opioid agonist indicated for the management of pain; Silenor, a medication indicated for the treatment of insomnia characterized by difficulty with sleep maintenance; and Khedezla, a prescription medication for major depressive disorder.
Its products also include CEDAX, an oral cephalosporin used for the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis, middle ear infection due to haemophilus influenza, or streptococcus pyogene; Zutripro and Rezira for the relief of cough and nasal congestion; Vituz, a hydrocodone bitartrate and chlorpheniramine maleate combination oral solution for the treatment of cough and allergies associated with the common cold; and OMECLAMOX-PAK, a gastroenterology product.
The company sells its products through its sales force and third-party sales organizations, as well as through its subsidiaries. It serves drug wholesalers, retail drug stores, mass merchandisers, and grocery store pharmacies in the United States. Pernix Therapeutics Holdings, Inc. was founded in 1996 and is headquartered in Morristown, New Jersey.